Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

Case Medical Research ◽

10.31525/ct1-nct04286607 ◽

2020 ◽

Author(s):

Keyword(s):

Plaque Psoriasis ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

British Journal of Dermatology ◽

10.1111/bjd.20595 ◽

2021 ◽

Author(s):

K.A. Papp ◽

M.G. Lebwohl ◽

L. Puig ◽

M. Ohtsuki ◽

S. Beissert ◽

...

Keyword(s):

Plaque Psoriasis ◽

Interim Analysis ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Term Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial

Dermatology and Therapy ◽

10.1007/s13555-021-00490-3 ◽

2021 ◽

Author(s):

Kim A. Papp ◽

Saskia de Vente ◽

Jiewei Zeng ◽

Mary Flack ◽

Byron Padilla ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Chronic Plaque Psoriasis ◽

Safety And Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Bimekizumab response maintenance through two years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Interim results from the BE BRIGHT open-label extension trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.5.supp.52 ◽

2021 ◽

Vol 5 (6) ◽

pp. s52

Author(s):

Bruce Strober ◽

Akihiko Asahina ◽

Ulrich Mrowietz ◽

Mark Lebwohl ◽

Peter Foley ◽

...

Keyword(s):

Plaque Psoriasis ◽

Severe Plaque Psoriasis ◽

Open Label Extension ◽

Extension Trial

N/A

Download Full-text

Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.128 ◽

2017 ◽

Vol 1 ◽

pp. s129

Author(s):

Alexa B Kimball ◽

Martin M Okun ◽

Gerit Mulder

Keyword(s):

Hidradenitis Suppurativa ◽

Open Label Extension ◽

Extension Trial

Abstract Not Available Disclosures: Study supported by AbbVie.

Download Full-text

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Case Medical Research ◽

10.31525/ct1-nct03836716 ◽

2000 ◽

Author(s):

Keyword(s):

Amyotropic Lateral Sclerosis ◽

Open Label Extension ◽

Extension Trial ◽

Lateral Sclerosis

Download Full-text

Open-Label, Extension Trial to Demonstrate the Effectiveness and Safety of L-CsA Plus Standard of Care in the Treatment of BOS in Patients Post Single or Double Lung Transplant

Case Medical Research ◽

10.31525/ct1-nct04039347 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Transplant ◽

Standard Of Care ◽

Open Label Extension ◽

Extension Trial

Download Full-text

An Open Label Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder

Case Medical Research ◽

10.31525/ct1-nct04186403 ◽

2019 ◽

Author(s):

Keyword(s):

Borderline Personality Disorder ◽

Personality Disorder ◽

Borderline Personality ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: An open-label extension trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736282945.793563275 ◽

2019 ◽

Author(s):

John Paul Leach

Keyword(s):

Nasal Spray ◽

Outpatient Treatment ◽

Safety And Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text

Disease-modifying effects of edasalonexent, an NF-κB inhibitor, in young boys with Duchenne muscular dystrophy: Results of the MoveDMD phase 2 and open label extension trial

Neuromuscular Disorders ◽

10.1016/j.nmd.2021.02.001 ◽

2021 ◽

Author(s):

Richard S. Finkel ◽

Erika Finanger ◽

Krista Vandenborne ◽

H. Lee Sweeney ◽

Gihan Tennekoon ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Phase 2 ◽

Open Label Extension ◽

Disease Modifying ◽

Extension Trial

Download Full-text

Long‐term safety and efficacy of add‐on cannabidiol in patients with Lennox–Gastaut syndrome: Results of a long‐term open‐label extension trial

Epilepsia ◽

10.1111/epi.17000 ◽

2021 ◽

Author(s):

Anup D. Patel ◽

Maria Mazurkiewicz‐Bełdzińska ◽

Richard F. Chin ◽

Antonio Gil‐Nagel ◽

Boudewijn Gunning ◽

...

Keyword(s):

Safety And Efficacy ◽

Open Label Extension ◽

Extension Trial

Download Full-text